-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Initiates Coverage On Ascendis Pharma with Outperform Rating, Announces Price Target of $205

Benzinga·04/16/2025 15:04:52
Listen to the news
RBC Capital analyst Luca Issi initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Outperform rating and announces Price Target of $205.